Evidence map›Paper›PMID 29562501›Full record

ArticleCancer biomarkers : section A of Disease markers2018

Is serum survivin expression a predictive biomarker in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy?

Yakup Bozkaya, Nuriye Yıldırım Özdemir, Sevilay Sezer, Osman Köstek, Nebi Serkan Demirci, Ozan Yazıcı, Gökmen Umut Erdem, Tülay Eren, Nurullah Zengin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Yakup BozkayaDepartment of Medical Oncology, SBÜ Ankara Numune Education and Research Hospital, Ankara, Turkey.
Nuriye Yıldırım ÖzdemirDepartment of Medical Oncology, SBÜ Ankara Numune Education and Research Hospital, Ankara, Turkey.
Sevilay SezerDepartment of Biochemistry, SBÜ Ankara Numune Education and Research Hospital, Ankara, Turkey.
Osman KöstekDepartment of Medical Oncology, Faculty of Medicine, Trakya University, Edirne, Turkey.
Nebi Serkan DemirciDepartment of Medical Oncology, SBÜ Ankara Numune Education and Research Hospital, Ankara, Turkey.
Ozan YazıcıDepartment of Medical Oncology, SBÜ Ankara Numune Education and Research Hospital, Ankara, Turkey.
Gökmen Umut ErdemDepartment of Medical Oncology, SBÜ Ankara Numune Education and Research Hospital, Ankara, Turkey.
Tülay ErenDepartment of Medical Oncology, SBÜ Ankara Numune Education and Research Hospital, Ankara, Turkey.
Nurullah ZenginDepartment of Medical Oncology, SBÜ Ankara Numune Education and Research Hospital, Ankara, Turkey.
Ankara Numune Eğitim ve Araştırma Hastanesi · TRSağlık Bilimleri Üniversitesi · TRTrakya University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe potential prognostic value of survivin is variably reported depending on the gastric cancer.

objectiveEvaluation of the prognostic and predictive significance of serum survivin and its relation with survival and treatment response rates in patients with locally advanced gastric cancer (LAGC).

methodsSerum samples were prospectively collected from 50 patients with newly diagnosed LAGC. Serum samples of 32 healthy subjects were also collected as control groups for survivin levels. Serum survivin levels were evaluated at baseline and after three cycles of neoadjuvant chemotherapy in LAGC patients.

resultsMedian survivin level was 147 IU/L (range = 4.4-4936) at baseline and was 27 IU/L (range = 4.2-4737) after neoadjuvant chemotherapy. The difference between survivin levels of the control group (26 IU/L, range = 3.8-1430) and pre-treatment patient group was statistically significant (p< 0.001). Clinical response to mDCF regimen was classified as progressive (progressive disease) and non-progressive groups (partial response + stable disease). Baseline survivin levels were similar between patients in progressive and non-progressive groups (p= 0.55). Survivin levels were significantly reduced after chemotherapy in non-progressive group (p< 0.001). In contrast, serum survivin levels increased in a stepwise fashion from baseline to post-chemotherapy in patients with progressive disease (p= 0.06). Patients were divided into low and high survivin groups according to baseline median survivin levels. Median DFS was 12.4 and 14.6 months for low and high groups, respectively (p= 0.18). Moreover, median OS was 14.4 and 24.9 months for low and high group, respectively (p= 0.14).

conclusionIt can be suggested that serum survivin can be used as a predictor of response to chemotherapy- but not survival- in LAGC patients receiving neoadjuvant mDCF chemotherapy. However, large multicenter prospective studies are required to confirm these results.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorChemotherapy, AdjuvantCisplatinDocetaxelFemaleFluorouracilHumansInhibitor of Apoptosis ProteinsMaleMiddle AgedNeoadjuvant TherapyStomach NeoplasmsSurvivinBiomarkers, TumorBIRC5 protein, humanCisplatinDocetaxelFluorouracilInhibitor of Apoptosis ProteinsSurvivinTaxoidslocally advanced gastric cancerModified DCFneoadjuvant chemotherapypredictivesurvivin

Identifiers

PMID29562501
PMCPMC13078440
OpenAlexW2790723406

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.